![]() 1998), while the determination of MSC concentration before cell expansion is still a challenge. The identification of HSCs is a relatively simple and frequently used method (Keeney et al. For stem cell therapies, identification and quantification of the stem cell population is crucial. 2013).Īlthough MSCs have been successfully isolated from almost all types of tissues, bone marrow is usually used as cell source for cell expansion in the most common clinical applications like GVHD treatment or replacement of bone tissue. 2010), additionally there are some reports regarding the prevention of GVHD after MSCs cotransplantation with HSCs (Ball et al. The majority of early phase clinical trials showed efficacy in the treatment of acute and chronic GVHD with MSCs (Kebriaei et al. Whereas, they can also function as negative effectors and inhibit proliferation and cytotoxic action of immune cells, which could be exploited to prevent or mitigate complication of graft-versus-host disease (GVHD) following allogeneic HSC transplantations. Namely, as secretors of hematopoietic cytokines, MSCs could be infused to promote hematopoiesis after myeloablative therapy (Koç et al. The complex paracrine signaling network is one of their main therapeutic mechanisms. 2013), and for the treatment of patients with autoimmune diseases (Maria et al. MSCs are gaining interest due to their role in tissue damage repair (DiMarino et al. In the last 20 years, mesenchymal stem cells (MSCs) are another bone marrow cell type often applied in cell therapies as well. Additionally, statistically significant higher CFU-F numbers were observed when bone marrow samples were harvested from three different sites from the anterior iliac crest instead of harvesting the same sample amount only from one site.īone marrow is a source of multipotential stem cells, including hematopoietic stem cells (HSCs) which are extensively used for the treatment of various malignant and non-malignant diseases for more than half a century (Eaves 2015 Passweg et al. An age-related quantitative reduction of hematopoietic CD45 dim/CD34 +, mesenchymal CD45 −/CD73 +/CD90 +/CD105 + and CD45 −/CD271 + stem cells, and CFU-F numbers were noted. The relationship between the hematopoietic CD45 dim/CD34 + cell concentration and mesenchymal CFU-Fs or CD45 −/CD271 + cells shows a positive linear regression. A positive correlation of MSC populations to the CFU-F numbers is observed, the population of the CD45 −/CD271 + cells correlates better with CFU-F numbers than the population of the CD45 −/CD73 +/CD90 +/CD105 + cells. ![]() Further, in donors of various ages, mesenchymal stem cell concentration was compared with the result of CFU-F assay and with hematopoietic stem cell concentration, determined by a standardized flow cytometric assay. To identify MSCs collected from bone marrow we have used two combinations of cell markers (CD45 −/CD73 +/CD90 +/CD105 + and CD45 −/CD271 +) and fibroblast colony-forming unit (CFU-F) assay. MSCs are relatively easy to expand in a cell culture, however determination of their concentration in harvested tissue is more complex and is not implemented as routine procedure. Mesenchymal stem cells (MSCs) are heterogeneous population of cells with great potential for regenerative medicine. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |